Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions
- Sponsor
- The University Clinic of Pulmonary and Allergic Diseases Golnik
- Study ID
- NCT02968394
- Status
- Unknown
Conditions
- Allergy
- Bee Venom
- Immunotherapy
- Omalizumab
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- omalizumab — DRUG
Study Details
The purpose of this study is to evaluate if omalizumab co-treatment may allow reintroduction of honey bee venom immunotherapy in patients with immunotherapy treatment failure due to systemic reactions.
Key Dates
- Start date
- Mar 31, 2014
- Status verified
- Nov 2016
- Primary completion
- Mar 31, 2017
Study Design
- Enrollment
- 11 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: NEVITCo treatment with omalizumab during another attempt of immunotherapy introduction
Primary Outcome Measure
Number of systemic reactions during ultra rush immunotherapy build up phase and maintenance phase followed by omalizumab co-treatment. [ Time Frame: 2 months ]
Central Contacts
- Peter Kopac, MD+386 4 25 69 100
Related Studies
- Understanding Allergies and Sensitizations in Healthy and Allergic IndividualsRecruiting · Stanford University · Palo Alto, California
- Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving ImmunotherapyRecruiting · Viome · Orlando, Florida
- A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.Recruiting · Oxford Biodynamics Inc. · Norwich, Connecticut
- Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung CancerRecruiting · VA Office of Research and Development · Long Beach, California